Clincosm LogoSign in Get a demo

Biliary Tract Neoplasms

Showing 1 - 25 of 53
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Biliary Tract Tumors Trial (Total Neoadjuvant Treatment)

Not yet recruiting
  • Biliary Tract Neoplasms
  • Total Neoadjuvant Treatment
  • (no location specified)
Sep 7, 2023

Biliary Tract Tumors, Immunotherapy Trial in Beijing (Durvalumab, Lenvatinib Oral Product, Chemotherapy)

Recruiting
  • Biliary Tract Neoplasms
  • Immunotherapy
  • Beijing, Beijing, China
    Chinese Academy of Medical Sciences & Peking Union Medical Colle
Jul 6, 2023

Biliary Tract Diseases, Gallbladder Cancer, Extrahepatic Bile Duct Cancer Trial (no interventions)

Not yet recruiting
  • Biliary Tract Diseases
  • +5 more
  • no interventions
  • (no location specified)
Jun 1, 2023

European Training Program for Robotic Liver Surgery (LIVEROBOT)

Not yet recruiting
  • Liver Diseases
  • +6 more
  • European Multicentre Training Program for Robotic Liver Surgery
  • (no location specified)
Feb 8, 2023

Biliary Tract Tumors, Gallbladder Cancer, Cholangiocarcinoma Trial in Seoul (Durvalumab + Gem/Cis, Gem/Cis)

Active, not recruiting
  • Biliary Tract Neoplasms
  • +2 more
  • Seoul, Korea, Republic of
    Asan Medical Center
Jan 30, 2023

UCAD for Diagnosing Benign or Malignant Biliary Obstruction and

Recruiting
  • Biliary Tract Neoplasms
  • +3 more
  • The level of CIN
  • Shanghai, Shanghai, China
    Xinhua Hospital
Jan 12, 2023

Biliary Obstruction, Pancreatic Cancer, Biliary Tract Tumors Trial in L'Hospitalet de Llobregat (Double pigtail plastic stent

Active, not recruiting
  • Biliary Obstruction
  • +2 more
  • Double pigtail plastic stent through lumen-apposing metal stent
  • Lumen-apposing metal stent without double pigtail plastic stent
  • L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain
  • +1 more
Dec 28, 2022

Hepatic Tumors, Biliary Tract Tumors, Pancreatic Tumors Trial in Seoul (Perioperative rehabilitation program, Conventional)

Completed
  • Hepatic Neoplasms
  • +2 more
  • Perioperative rehabilitation program
  • Conventional
  • Seoul, Korea, Republic of
    Asan Medical Center, University of Ulsan College of Medicine
Nov 16, 2022

Biliary Tract Tumors Trial in Belgium, France, United Kingdom (Futibatinib, Ivosidenib, Zanidatamab)

Not yet recruiting
  • Biliary Tract Neoplasms
  • Brussels, Belgium
  • +56 more
Nov 7, 2022

Capecitabine Versus S-1 as Adjuvant Therapy in Biliary Tract

Recruiting
  • Biliary Tract Neoplasms
  • +3 more
  • Shanghai, China
    Huashan hospital
Aug 16, 2022

Uterine Tumors, Uterine Cervical Tumors, Biliary Tract Tumors Trial in Worldwide (tucatinib, trastuzumab, fulvestrant)

Recruiting
  • Uterine Neoplasms
  • +5 more
  • Goodyear, Arizona
  • +63 more
Aug 15, 2022

Carcinoma, Hepatocellular, Colorectal Tumors, Pancreatic Ductal Adenocarcinoma Trial in Worldwide (Pembrolizumab, Belzutifan,

Recruiting
  • Carcinoma, Hepatocellular
  • +5 more
  • Duarte, California
  • +39 more
Jul 29, 2022

Biliary Tract Cancer, Cholangiocarcinoma, Biliary Tract Tumors Trial in Pittsburgh (Tumor Infiltrating Lymphocytes (TIL))

Recruiting
  • Biliary Tract Cancer
  • +2 more
  • Tumor Infiltrating Lymphocytes (TIL)
  • Pittsburgh, Pennsylvania
    Allyson Welsch
Jul 21, 2022

Biliary Disease, Pancreatic Disease, Choledocholithiasis Trial in Palo Alto (Duodenoscope with single-use distal cover,

Not yet recruiting
  • Biliary Disease
  • +5 more
  • Duodenoscope with single-use distal cover
  • Conventional duodenoscope
  • Palo Alto, California
    Stanford hospital
Jun 17, 2022

Biliary Tract Tumors Trial (Envafolimab plus Gemcitabine&Cisplatin, Gemcitabine&Cisplatin)

Not yet recruiting
  • Biliary Tract Neoplasms
  • (no location specified)
Jun 8, 2022

Bile Duct Stricture, Endoscopic Retrograde Cholangiopancreatography, Biliary Disease Trial in Beijing (Transparent cap)

Recruiting
  • Bile Duct Stricture
  • +3 more
  • Transparent cap
  • Beijing, Beijing, China
    The Fifth Medical Center of Chinese PLA General Hosptial
Apr 14, 2022

Study of Patients With Malignant Mesothelioma

Recruiting
  • Mesothelioma
  • +4 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    Apr 7, 2022

    Biliary Tract Tumors, Liver Cancer, Hepatocellular Carcinoma Trial run by the NCI (Durvalumab, Tremelimumab, Trans-arterial

    Active, not recruiting
    Has Results
    • Biliary Tract Neoplasms
    • +4 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Mar 1, 2022

    Biliary Tract Tumors Trial in United States (Gemcitabine, Cisplatin, Ipilimumab)

    Active, not recruiting
    Has Results
    • Biliary Tract Neoplasms
    • Atlanta, Georgia
    • +6 more
    Jan 3, 2022

    Biliary Tract Tumors Trial (TST001)

    Not yet recruiting
    • Biliary Tract Neoplasms
    • (no location specified)
    Dec 28, 2021

    Biliary Tract Tumors, Cholangiocarcinoma, Bile Duct Cancer Trial run by the NCI (Pembrolizumab (MK-3475), Oxaliplatin,

    Completed
    Has Results
    • Biliary Tract Neoplasms
    • +4 more
    • Pembrolizumab (MK-3475)
    • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Dec 1, 2021

    Biliary Tract Tumors Trial in Seoul (Durvalumab, Tremelimumab, Gemcitabine)

    Active, not recruiting
    • Biliary Tract Neoplasms
    • Seoul, Korea, Republic of
      Seoul National University Hospital
    Oct 26, 2021

    Hepatobiliary Tumor, Liver Tumor, Biliary Tract Tumors Trial in Beijing (axitinib plus toripalimab)

    Recruiting
    • Hepatobiliary Neoplasm
    • +2 more
    • axitinib plus toripalimab
    • Beijing, Beijing, China
      Peking Union Medical College Hospital
    Aug 17, 2021

    Combinatory EUS and ERCP in Unclear Lesions

    Completed
    • Neoplasms
    • +3 more
    • Combinatory EUS and ERCP
    • Gothenburg, Sweden
      Sahlgrenska University Hospital
    Dec 19, 2020

    Biliary Tract Tumors, Gastric Cancer, Esophageal Squamous Cell Carcinoma Trial in Beijing (FGFR Inhibitor, IDH1 Inhibitor, HER2

    Unknown status
    • Biliary Tract Neoplasms
    • +8 more
    • FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al.
    • Other Therapy
    • Beijing, Beijing, China
      Peking University Cancer Hospital
    Oct 8, 2020